# Thalidomide and birth defects

<table>
<thead>
<tr>
<th>Journal:</th>
<th>eLS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>A26052.R1</td>
</tr>
<tr>
<td>Wiley - Manuscript type:</td>
<td>Standard Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Fraga, Lucas; University of Aberdeen, Diamond, Alex; University of Aberdeen, Vargesson, Neil; University of Aberdeen,</td>
</tr>
</tbody>
</table>

### Abstract:
Thalidomide is a teratogenic drug that caused horrific birth defects when prescribed as an antiemetic to pregnant women in the 1960’s. The most stereotypical defect is symmetrical limb malformations such as phocomelia, though ear, eye and internal organ defects are also observed. Thalidomide was consequently withdrawn from the market. However, Thalidomide has since been shown to have many beneficial anti-inflammatory and immunomodulatory effects and is therefore used in a regulated manner in the treatment against cancers and inflammatory disorders. Sadly, new cases of babies affected by thalidomide are being born in Brazil, likely due to medicine sharing. The mechanisms of how thalidomide causes a wide range of embryonic malformations are becoming clearer; thalidomide is thought to act through molecules such as cereblon and tubulin and also affect blood vessel development and cell death, resulting in teratogenesis. Fully understanding the molecular events induced by thalidomide is essential if we are to develop a safe but clinically relevant form of the drug.
Thalidomide and Birth Defects

Lucas Rosa Fraga*, Alex J Diamond*, Neil Vargesson$

School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK

Advanced Article

* - These authors contributed equally to this Review Article.

$ - Author for correspondence: email: n.vargesson@abdn.ac.uk; nvargesson@gmail.com. Tel: (0)1224 437374
Abstract

Thalidomide is a teratogenic drug that caused horrific birth defects when prescribed as an antiemetic to pregnant women in the 1960s. The most stereotypical defect is symmetrical limb malformations such as phocomelia, though ear, eye and internal organ defects are also observed. Thalidomide was consequently withdrawn from the market. However, Thalidomide has since been shown to have many beneficial anti-inflammatory and immunomodulatory effects and is therefore used in a regulated manner in the treatment against cancers and inflammatory disorders. Sadly, new cases of babies affected by thalidomide are being born in Brazil, likely due to medicine sharing. The mechanisms of how thalidomide causes a wide range of embryonic malformations are becoming clearer; thalidomide is thought to act through molecules such as cereblon and tubulin and also affect blood vessel development and cell death, resulting in teratogenesis. Fully understanding the molecular events induced by thalidomide is essential if we are to develop a safe but clinically relevant form of the drug.

Key Words

angiogenesis, cell death, Cereblon, reactive oxygen species, time sensitive window, mechanisms of teratogenesis, chicken embryo, zebrafish embryo

Key Concepts

- Thalidomide was used between 1957 and 1961 as a ‘safe’ treatment for morning sickness, but was withdrawn after it was found to cause severe birth defects.
- Thalidomide has since been shown to possess anti-inflammatory, antiangiogenic and anti-proliferative properties.
• Thalidomide is now used, under strict regulations, to treat human inflammatory disorders and cancer.
• Thalidomide causes embryonic damage in a short time-sensitive window between day 20 and 36 post-fertilisation in humans.
• Thalidomide causes damage to the majority of the body tissues, amongst the most common and stereotypical damage is to the limbs.
• Effects of thalidomide can vary dependent on the species exposed, some species being more sensitive to the drug than others.
• Evidence supports blood vessels as a primary target of thalidomide.
• Possible other pathways involved in thalidomide-induced embryopathy are oxidative stress induction, cell death and binding to Cereblon.
• Cereblon acts as a target of thalidomide for treatment of multiple myeloma in adult humans.
1 History of Thalidomide

Thalidomide [α-(N-phthalimido) glutaramide] was synthesised by Chemie Grunenthal, in Germany, and introduced onto the market in 1957 as a “safe”, non-addictive, over-the-counter sedative (Vargesson, 2015). The drug was marketed across 46 countries and was also sold as an effective antiemetic for pregnant women suffering morning sickness (Franks et al., 2004; Vargesson, 2009; Vargesson, 2013; Vargesson, 2015).

Following the release of thalidomide, reports of an increase in the occurrence of severe and rare birth defects began surfacing (McCredie, 2009; Vargesson, 2013; Vargesson, 2015). The most striking defect was phocomelia of the limbs (where distal structures of the limb remain whereas proximal structures are lost or reduced), though some babies presented with amelia (no limb structures exist). A wide range of damage to the limbs could be observed as well as damage to many other body systems (see Section 3) (Lenz and Knapp, 1962; Ruffing, 1977). Damage to the ears, eyes, genitalia, heart, gastrointestinal tract and kidneys was also reported (Smithells and Newman, 1992; Vargesson, 2009; Vargesson, 2013; Vargesson, 2015). The range and severity of damage to many babies across Europe confused clinicians at the time. It was not till two clinicians, McBride in Australia and Lenz in Germany, independently concluded in 1961 that the children with these birth defects were born to mothers who had consumed thalidomide (McBride, 1961; Lenz, 1962; Lenz, 1988). The drug was withdrawn from the worldwide market on 30 Nov 1961 (Matthews and McCoy, 2003; Vargesson, 2013). The consumption of thalidomide during pregnancy was confirmed as the cause of birth defects since there was an almost complete loss of such defects from 1962 onwards (Lenz, 1988; Smithells and Newman, 1992; Vargesson, 2013; Vargesson, 2015). However, it is estimated that at least 10,000 children were born with deformities resulting from thalidomide exposure (Smithells and Newman, 1992; Vargesson, 2009). Thalidomide was not approved for use in America during the 1957-1962 thalidomide disaster: Dr Frances Kelsey, working for the US Food and Drug Administration (FDA), doubted its safety after reports of peripheral neuropathy in patients (Matthews and McCoy, 2003; Franks et al., 2004; Vargesson, 2013; Vargesson, 2015). If thalidomide had been released in
the US, there may have been a significantly higher number of cases of birth defects, as seen in Europe, Canada, Australia and Japan.

Thalidomide underwent a rebirth in 1965 after studies proved its effectiveness as a treatment for erythema nodosum leprosum (ENL), a complication of leprosy (Sheskin, 1965). Following this, thalidomide was licensed in Mexico, Brazil and later in the US for the use in the treatment of ENL (Franks et al., 2004) and in 2006 for treatment of multiple myeloma (MM) (Latif, 2012).

Programs now administer the use of thalidomide under strict guidelines where women prescribed the drug are required to use birth control and take regular pregnancy tests. When these guidelines are followed, no occurrence of thalidomide embryopathy has been reported (Uhl et al., 2006). However, tragically, in Brazil, children are still being born with thalidomide embryopathy where the drug is used to effectively treat leprosy. This is likely due to a culture of sharing medicines as a result of people living so far away from hospitals, misinterpretation of the drug, and pregnant women taking it whilst suffering from leprosy (Vianna et al., 2013; Vargesson, 2013). Considering the beneficial properties of thalidomide there is the possibility of increased use and a concern for a further potential increase in the frequency of thalidomide-induced birth defects. Despite research efforts the mechanisms of thalidomide-induced embryopathy are not fully understood. Continuing research is vital in the mission to synthesise a safe, clinically relevant form which is non-teratogenic, i.e. does not cause birth defects.

2 Biochemistry of thalidomide

Thalidomide is a derivative of the non-essential amino acid glutamic acid (Franks et al., 2004). The structure consists of a glutarimide ring, pthalimido ring and contains an asymmetric carbon atom (Figure 1). The presence of the chiral carbon allows thalidomide to exist in two, interchangeable states, or enantiomers (S(-)) and R(+)), within the body. One state is thought to be the causative ‘teratogenic’ state (S(-)), and the other the ‘sedative’ state (R(+)). Since the drug can switch states within the body, it is not conceivable to prescribe just the ‘safe’, ‘sedative’ version. Thalidomide can broken down in to its active state by the liver enzyme cytochrome P450 and has
a half-life of 6-12 hours. Thalidomide can also rapidly hydrolyse in bodily fluids (Franks et al., 2004; Vargesson, 2009; Vargesson, 2013; Vargesson, 2015).

2.1 Pharmacological Properties of Thalidomide

Further research into the mechanism of thalidomide action has revealed a wide, diverse range of functions. As well as being anti-inflammatory and immunomodulatory, thalidomide is also anti-angiogenic and has anti-proliferative activities (D’Amato et al., 1994; El-Aarag et al., 2014). Through these properties thalidomide has been identified as an effective treatment for a number of adult conditions. Indeed since the discovery in 1965 that thalidomide can be beneficial as an anti-inflammatory drug to treat ENL, studies have recognised its clinical purpose as treatment for multiple myeloma (MM), cancers, Behçet’s disease, gastrointestinal disorders, rheumatological disorders, hereditary hemorrhagic terangiectasia (HHT), lupus, idiopathic pulmonary fibrosis, HIV and diabetic retinopathy (Franks et al., 2004; Vargesson, 2013; Vargesson, 2015).

2.1.1 Antiangiogenic actions

Thalidomide has the ability to inhibit angiogenesis, the formation of new and remodelling blood vessels. This action was first reported by using rabbit and rodent cornea assays to show that thalidomide inhibits fibroblast growth factor (FGF)-induced angiogenesis (D’Amato et al., 1994). In chicken embryos thalidomide inhibits nitric oxide (NO), an important molecule for endothelial cell function and protection of blood vessels (Siamwala et al., 2012; Majumdar et al., 2009; Tamilarasan et al., 2006; see also DOI: 10.1002/9780470015902.a0003390.pub2). NO is required for normal limb development since it promotes angiogenesis and reduces oxidative stress, therefore inhibition by thalidomide leads to limb malformations. Indeed, thalidomide affected chicken and zebrafish embryos can be rescued by NO (Siamwala et al., 2012). Additionally, thalidomide inhibits NO-induced endothelial cell migration as well as interfering with normal actin polymerisation patterns. This prevents cells forming tubes, thereby inhibiting angiogenesis at the cellular level (Tamilarasan et al., 2006; Vargesson, 2013; Vargesson, 2015).

Thalidomide also induces degradation of Tumor Necrosis Factor-α (TNFa) mRNA, a pro-angiogenic cytokine, suggesting another mechanism by which thalidomide
inhibits angiogenesis (Moreira et al., 1993). Thalidomide has been demonstrated to reduce the vascular hemorrhaging and malformations in patients suffering from HHT by inhibiting angiogenesis and through recruitment of mural cells, known to decrease endothelial cell migration and proliferation, causing early maturation of blood vessels (Lebrin et al., 2010; Figure 2). In zebrafish embryos, thalidomide reduces VEGF receptor function (Yabu et al., 2005; Vargesson, 2013; Vargesson, 2015). In chicken embryos, exposure of early blood vessels to thalidomide results in a breakdown of vascular formation (Tamilarasan et al., 2006). Antiangiogenic analogs of thalidomide, as opposed to anti-inflammatory analogs, cause limb defects (Therapontos et al., 2009). The antiangiogenic actions of the drug make it a promising therapeutic agent for the treatment of tumors, since it can prevent their early vascularisation (Therapontos et al., 2009).

2.1.2 Anti-proliferative actions

The anti-proliferative effects of thalidomide are independent of its immunomodulatory activities in hematologic malignancies. Thalidomide reduces proliferation of cancerous MM cells that are resistant to standard chemotherapy (Melcherd and List, 2007). Myeloma cells are targeted by thalidomide through several mechanisms including activation of antitumor immunity and exertion of antiangiogenic effects. The treatment of MM patients with thalidomide improves their survival rate, but the exact way in which thalidomide achieves this is not fully understood. Current studies are pointing to a molecular pathway targeted by thalidomide to combat MM which involves Cereblon, Ikaros and Aiolos proteins. Cereblon is part of an E3 ubiquitin ligase complex with the proteins Damaged DNA binding protein 1 (DDB1), Cullin-4A (CUL4A), and regulator of Cullin1 (Roc1). This complex tags proteins with ubiquitin, labelling them for proteolysis, and is therefore important for the regulation of protein expression (Stewart, 2014; Ito et al., 2010; Ito et al., 2011). After binding to thalidomide, Cereblon protein is inactivated, resulting in the rapid ubiquitination and degradation of Ikaros and Aiolos. Both proteins are transcription factors that in normal conditions regulate T and B cell development. High degradation of Ikaros and Aiolos increase the Interleukin-2 (IL) levels and decreases TNFα levels (Stewart, 2014) (Figure 2). In addition, a correlation exists between low amounts of Cereblon in MM cells, clinical drug resistance and poor survival outcomes (Schuster et al., 2014; Stewart, 2014). Thalidomide reduces expression of TNFα, NF-κB, IL-6 and IL-8.
and Vascular Endothelial Growth Factor (VEGF) proteins which are related to tumour cell survival, proliferation, inhibition of apoptosis and resistance to therapy (Latif et al., 2012).

2.1.3 Anti-inflammatory actions

Thalidomide exhibits immunomodulatory and anti-inflammatory effects through TNFα mRNA degradation, Nuclear Factor-kappa-B (NF-κB) regulation and Cyclooxygenase-2 (COX2) inhibition (Moreira et al., 1993; Vargesson, 2015). Inducing TNFα mRNA degradation suppresses the activation of interleukins and cytokines by monocytes and macrophages. ENL patients present with high levels of TNFα, which reduce with thalidomide treatment (Sampaio, 1993; Vargesson, 2013). The effects of thalidomide on TNFα is beneficial when treating other autoimmune diseases which arise through an overproduction of inflammatory cytokines (Latif et al., 2012). A key regulator of the expression of cytokines, including TNFα, is transcription factor NF-κB. Thalidomide selectively blocks TNFα and hydrogen peroxide-induced NF-κB activation, interfering with TNFα expression and other inflammatory molecules such as IL-8 (Majumdar et al., 2002). Cytokine COX-2, involved in both inflammatory response and cancer growth, is also suppressed by thalidomide (Melcherd and List, 2007).

In addition to these actions which are the basis for some of thalidomide’s clinical applications the drug can also induce cell death (Knobloch et al., 2007) as well as reactive oxygen species (ROS) (Parman et al., 1999). The multiple and varied actions of the drug, in part, explain why it has been so difficult to determine the precise mechanism underlying thalidomide induced teratogenesis. As we will see current viewpoints favour the antiangiogenic action of the drug as a major cause of teratogenesis.

3 Thalidomide Embryopathy: What damage does thalidomide cause?

3.1 Thalidomide acts in a time sensitive window
Thalidomide induces damage to the embryo in a time-sensitive window between days 20 and 36 post-fertilization (Figure 3) (Vargesson, 2009; Vargesson, 2015). The timing of damage was determined through interviews with mothers who had taken thalidomide, providing data to identify a correlation between when thalidomide was taken and the resulting malformations (Lenz and Knapp, 1962; Ruffing, 1977; Smithells and Newman, 1992). Since the symptoms of typical morning sickness coincide with a period of rapid development and embryogenesis, thalidomide was taken at a time when countless cell divisions, growth, migration, differentiation and organogenesis are occurring. Exposure to thalidomide interfered with major developmental events, triggering the defects seen in thalidomide embryopathy (Vargesson, 2013). Miscarriage results if the drug is taken before the time-sensitive window (Vargesson, 2015), however it is not known whether exposure to thalidomide after day 36 results in obvious embryonic defects. The babies identified for study and maternal interview had mainly outward, visible defects and so if damage was only obvious later in life, it was not noted. Therefore exposure to thalidomide after the time-sensitive window may not be harmless. Some reports suggest it would be rare for any embryo to be unharmed following consumption of just one tablet (Smithells and Newman, 1992). Indeed, it is estimated that one 50mg tablet is sufficient to cause birth defects in at least 20-50% of embryos exposed to thalidomide during the time-sensitive window (McBride, 1961; Lenz, 1962; Smithells and Newman, 1992; Vargesson, 2009; Vargesson, 2013; Vargesson, 2015).

3.2 Thalidomide Embryopathy

Although almost any organ can be affected by thalidomide, the type of malformations observed are dependent on the day of thalidomide intake (Table 1; Figure 3) (Lenz and Knapp, 1962; Ruffing, 1977; Smithells and Newman 1992; Vargesson, 2015). The multi-tissue damage seen is referred to as thalidomide embryopathy (Table 1) where bilateral, symmetrical limb malformation is the most stereotypical defect, but many other body systems are damaged too (Newman, 1986; Smithells and Newman, 1992). Furthermore, thalidomide embryopathy has also been termed thalidomide syndrome, as the damage seen is a collection of damage often occurring independently in other human conditions (Newman, 1986; Smithells and Newman, 1992; Vargesson, 2009; Vargesson, 2013) (see also DOI: 10.1002/9780470015902.a0025686).
3.2.1 Limb Damage

Phocomelia is the most striking limb malformation associated with thalidomide embryopathy, the most severe form of which being the absence of any long bones. The majority of thalidomide survivors have limb defects, ranging from amelia (no limb) to triphalangeal thumb and including radial dysplasia, and phocomelia. The majority of limb anomalies seen in thalidomide survivors are reduction events and typically bilateral in nature (Table 1). The thumb is the first bone to be affected, followed by the radius, humerus and ulna (Lenz and Knapp, 1962; McCredie, 2009; Smithells and Newman, 1992; Vargesson, 2013). Lower limb defects are less commonly seen. Shoulder and hip joints can be weaker in thalidomide survivors and the hip and pubic bones may be missing (Vargesson, 2013).

3.2.2 Ear and Eye Damage

Ears and eyes develop around the same time as the limbs in the embryo and so are targeted during the thalidomide time-sensitive window (Figure 3). Complete absence of the eyes, small eyes and poor vision are all reported defects. Unlike limb defects, eye defects can occur unilaterally. Ear defects usually occur bilaterally and in conjunction with eye defects and facial palsies. Malformations range from absence of the ear (anotia), resulting in deafness, to elements of the outer ear remaining (microtia) (Vargesson, 2013; Vargesson, 2015).

3.2.3 Facial and Neural Damage

Facial muscles and nerves can be damaged by thalidomide and lead to facial palsy or asymmetry. A stereotypical sign of thalidomide exposure is an enlarged facial naevus at birth, usually on the forehead, though this is no longer visible by three years of age (Vargesson, 2013). Irregular teeth, cleft palate and small noses are additional defects seen in thalidomide survivors. A second consequence of nerve damage by thalidomide during development is an increased occurrence of epilepsy and autism later in life (Smithells and Newman, 1992; Miller et al., 2005).

3.2.4 Internal Organ Damage

The frequency of internal organ defects is difficult to define since they are not obviously apparent and may not present during childhood. Only the most noticeable
defects will have been recorded during the 1960s. The heart, kidney, gastrointestinal and urinary tracts and genitalia can all be affected by exposure to thalidomide (Lenz and Knapp, 1962; Ruffing, 1977; Smithells and Newman, 1992). Heart malformations can occur with pulmonary stenosis and patent duct arteriosus and are thought to be the main cause of miscarriages or postnatal deaths suffered after intake of thalidomide. Kidney defects include rotated, hypoplastic and ectopic kidneys. Internal and external genital defects as well as urinary tract defects are also seen. Testicular absence or malformations in males and abnormalities of the uterus in females are known defects (Lenz and Knapp, 1962; Ruffing, 1977; Smithells and Newman, 1992; Vargesson, 2013; Vargesson, 2015).

The true scale of the number of affected embryos and/or the range of defects caused by thalidomide may never be known since many malformed babies will have not survived to birth, or died shortly after (Smithells and Newman, 1992; Vargesson, 2013; Vargesson, 2015). Furthermore, the criteria for diagnosis of thalidomide embryopathy was established in the 1960’s based upon the most severely affected children (Lenz and Knapp, 1962; Ruffing, 1977; Smithells and Newman, 1992). It is possible that children born without the classical thalidomide embryopathy phenotype and therefore not considered damaged by thalidomide could have had some embryonic malformations internally and perhaps late onset disorders. Certainly analysis and follow up of affected children was done very differently in the 1960’s than if the disaster had occurred today.

4 How does Thalidomide Cause Damage To The Embryo?

4.1 Thalidomide effects are species dependent

Initial studies by Grunenthal, who invented and marketed the drug, tested thalidomide on rodents, where no defects were detailed or described. Questions remain about the precise testing carried out, but Grunenthal say they carried out testing that was typical of the day. The drug was considered safe and approved for use. After thalidomide was withdrawn from the market it was actually found to act in many species including humans, primates, rabbits, marsupials, zebrafish and chickens (Stephens, 2009; Vargesson, 2013).
Rodents are sensitive to thalidomide but much less so than other organisms, and are affected by much higher doses (DiPaolo et al., 1964; Parkhie and Webb, 1983; Vargesson, 2013). The reason for this species sensitivity difference is unclear. Thalidomide is able to inhibit angiogenesis in mice and rat aortic ring cultures, so although rodents are not insensitive to the drugs mechanisms, there may be aspects such as different rates of metabolism which offer them protection (Lu et al., 2004). Indeed, incubation of thalidomide with rodent liver cytochrome enzymes results in lower angiogenic activity than if incubated with human or rabbit enzymes (Marks et al, 2002). Clearance of the drug is also much faster in mice compared to humans, so teratogenic forms may not exist for as long (Lu et al., 2004; Vargesson, 2013). Differences in the length of gestation between rodents and humans could also be a factor in predisposition of sensitivity to thalidomide.

Among the mammals, primates are considered the best model to study thalidomide embryopathy giving phenotypes that most similarly reflect those seen in humans (Ema et al., 2010; Vargesson, 2013; Vargesson, 2015). However primates present ethical and practical challenges including low offspring numbers, long gestation times and are costly to work with. Studies in non-human primates have shown characteristic limb reduction malformations, ranging from amelia to phocomelia, and defects in the tail and genitalia (Ema et al., 2010). Rabbit model studies identified a range of defects similar to those found in humans, including limb and internal organ defects (Fratta, 1965). Rabbits are therefore one of the most reliable models used to demonstrate the teratogenic effects of thalidomide. Regarding non-mammalian models, thalidomide is toxic to *Xenopus* and exposure causes teratogenic effects (Fort et al., 2000). Chicken and zebrafish embryos are excellent for studying thalidomide embryopathy since they develop rapidly and provide easy access to follow development (Stephens, 2009; Vargesson, 2009; Vargesson, 2013). Since these models are perfect for drug screening studies, the effect of thalidomide upon their development is well established making these animal models excellent for the study of thalidomide teratogenicity. In the chicken embryo, thalidomide causes limb and eye defects (Knobloch et al., 2007; Stephens, 2009; Therapontos et al., 2009; Ito et al., 2010; Mahony et al., 2013; Siamwala et al., 2012). In Zebrafish, embryonic fins and eyes are affected (Ito et al., 2010, Mahony et al., 2013; Yabu et al., 2005). In humans thalidomide affects the development of embryos in a time-sensitive manner.
This is also true for other animals, so embryos will be most sensitive to thalidomide during a particular window of development (Stephens, 2009; Therapontos et al., 2009; Ito et al., 2010; Mahony et al., 2013). Thalidomide also exhibits intra-species specificity; of eight dizygotic twin pairs examined during the 1960s thalidomide disaster in Brazil, only four pairs were born with the same malformations (Schmidt and Salzano, 1980). Drug distribution, metabolism and the genetic background of each species, strain or individual must be taken in account.

4.2 Morphological and Molecular Actions of Thalidomide Teratogenicity

More than 30 theories attempting to explain the mechanisms of thalidomide teratogenesis have been postulated since the 1960s, though most cannot be backed up with in-vivo evidence (Vargesson, 2009; Vargesson, 2015). These theories include actions on DNA, bone cells, integrins and many others. Explanations need to address the range of defects seen in thalidomide embryopathy and how the time-sensitive window of exposure affects all tissues. Three of the most widely accepted theories are (i) the antiangiogenic action of the drug; (ii) the drugs ability to induce reactive oxygen species (ROS) and cell death; (iii) thalidomide binding to Cereblon.

4.2.1 Blood Vessels as Targets of Thalidomide

Blood vessels supply oxygen and nutrients to growing tissues so are essential for embryonic development. It is established that loss or disruption of blood vessels during embryogenesis can lead to death or embryonic malformations (Vargesson, 2003; Vargesson, 2013). It was postulated that limb defects might be caused by the antiangiogenic effect of thalidomide (D’Amato et al., 1994). Indeed damage to vessels can cause limb defects in chicken embryos (Vargesson and Laufer, 2001; Vargesson, 2003; Vargesson, 2009). Studies in chicken embryos have further demonstrated that thalidomide affects angiogenesis even before the expression of some signalling molecules essential for limb development, such as FGFs (Therapontos et al., 2009).

Thalidomide can be broken down into various by-products, and a large number of structural analogs of thalidomide can be synthesised. This is invaluable to help understand drug function and actions and also determine which characteristic of the
drug is the cause of teratogenesis. The production of CPS49, an antiangiogenic analog, has shed light on the method of teratogenesis. Blood vessels are destroyed within one hour of exposure to CPS49 in an E2.5 chicken embryo, with phocomelia presenting 7 days later (Therapontos et al., 2009; Vargesson, 2009). Cell death is observed after application of CPS49, as well as loss of Fgf8 and Sonic Hedgehog (Shh) expression, both key regulators of limb development and outgrowth. Thalidomide has also been shown to induce cell death and cause the loss of limb signalling events in chicken embryos (Knobloch et al., 2007). Studies indicate that CPS49 destroyed newly forming vessels without a smooth muscle coat. Smooth muscle protects vessels and prevents angiogenesis. In-vitro studies demonstrated that smooth muscle negative vessels undergoing angiogenesis were destroyed but mature, smooth muscle positive vessels were unharmed (Therapontos et al., 2009). CPS49 also disrupts blood vessels in zebrafish embryos and both CPS49 and thalidomide inhibit the actin cytoskeleton of vascular cells in-vitro (Therapontos et al., 2009; Tamilarasan et al., 2006; Lebrin et al., 2010).

4.2.2 Reactive Oxygen Species (ROS) and Cell Death

The production of ROS in embryos causes oxidative stress, cell death and is upregulated in presence of thalidomide (Vargesson, 2013; Vargesson, 2015). Oxidative stress is required for cell-death-dependent thalidomide embryopathy; therefore this model could explain damage to limbs and other tissue. If thalidomide increases production of ROS, this will lead to cell death in affected tissues, causing defects. The function of redox-sensitive NF-κB is also affected by oxidative stress. NF-κB is a transcription factor important for limb development, and thalidomide diminishes its ability to bind to DNA promoter targets. This alters expression of Fgf8, Fgf10 and Bone Morphogenetic Proteins (BMP) (Hansen and Harris, 2004), important genes in the process of limb development. Indeed, it has been shown that thalidomide exposure results in upregulation of Bmp-4, -5 and -7 expression in chicken embryos (Knobloch et al., 2007). However, just how thalidomide induces ROS and/or cell death in a time-sensitive and tissue specific manner is unclear, though it could be a secondary effect to the loss of blood vessels. Considering that oxidative stress is a physiological process and occurs during embryogenesis, how it causes tissue specific damage is unknown. It is understood that NF-κB can negatively regulate BMP signalling which could explain, in part, why limbs are
affected by thalidomide through oxidative stress. How the other tissues are affected and how the range of damage is caused remains unclear.

4.2.3 Cereblon and E3 Ubiquitin-ligase Complex

Thalidomide is proposed to initiate teratogenesis by binding Cereblon, preventing establishment of the E3 ubiquitination complex and consequently causing mis-regulation of developmental signalling molecules (Ito et al., 2010; Ito et al., 2011; Stewart et al., 2014; Vargesson, 2015).

In adult humans the Cereblon (CRBN) gene, conserved in species including plants and invertebrates (Higgins et al., 2004), is expressed in several tissues such as the testis, spleen, liver, pancreas, lung and skeletal muscle (Xin et al., 2008). Cereblon was identified as a primary binding target of thalidomide (Ito et al., 2010), supported by results showing mutations preventing the binding between Cereblon and thalidomide suppressed limb loss in chicken embryos (Ito et al., 2010). In addition, through inhibiting the translation of Cereblon mRNA, in zebrafish embryos, some phenotypes were found that appeared similar to those seen in thalidomide treated embryos, though not with the range or severity of damage seen in human thalidomide embryopathy (Ito et al., 2010). Furthermore, Cereblon loss-of-function mice appear normal and unharmed (Lee et al., 2013). Data suggests a participation of Cereblon in thalidomide embryopathy; however how thalidomide binding to Cereblon causes the damage, the range of damage and in a time sensitive manner is unclear, as is the precise role/function of Cereblon in normal embryonic development.

Thalidomide binding to Cereblon has been shown to mediate thalidomide’s beneficial anti-inflammatory and anti-myeloma actions in adult and diseased tissues (Figure 2). The downstream targets of Cereblon-Thalidomide binding relating to teratogenesis, however, are not known.

4.2.3 Tubulin

Through the use of an antiangiogenic thalidomide analog, 5HPP-33, biochemical and computational assays have shown the affinity of 5HPP-33 to bind tubulin. In addition, 5HPP-33 causes depolymerisation of microtubules and affects rebuilding of mitotic spindles, interfering with the alignment of chromosomes at metaphase (Rashid et al.,
For Review Only

Changes in actin and microtubule cytoskeleton cause actin stress fibre and microtubule depolymerisation, altering cell migration and proliferation. Thalidomide exposure to human umbilical vein endothelial cells (HUVECs) results in a disruption of actin cytoskeleton (Tamilarasan et al., 2006), and CPS49 affects migration and cytoskeletal organisation of endothelial cells (Therapontos et al., 2009).

These studies provide evidence that tubulin may be a target of thalidomide preventing angiogenesis, leading to cell death of tissues causing thalidomide teratogenesis.

4.2.4 Soluble Guanyl Cyclase and Nitric Oxide

Thalidomide has also been shown to potentially interact with soluble guanylyl cyclase (sGC). sGC stimulation by NO leads to production of cyclic guanosine monophosphate (cGMP) which is involved in several cellular processes, including apoptosis, vasodilation and blood flow increase through the control of vascular smooth muscle (Majumder et al., 2009, Siamwala et al., 2012). Experiments in HUVEC cultures showed that thalidomide exposure reduced cGMP levels, causing failure of angiogenesis. This phenotype can be reversed by inducing an increase in sGMP levels (Majumder et al., 2009).

Moreover, thalidomide has been shown to exert effects through alterations in NO-mediated endothelial cell migration and apoptosis (Tamilarasan et al., 2006, Siamwala et al., 2012). Assays in chicken embryos show increasing NO may rescue thalidomide teratogenicity (Tamilarasan et al., 2006, Majumder et al., 2009, Siamwala et al., 2012).

4.2.5 Genetic Studies

Many other gene expression patterns have been shown to be altered following thalidomide exposure in chicken, zebrafish and non-human primate studies including, for example, Shh, Fgf8 and Integrins (Vargesson, 2009; Vargesson, 2015). How these fit into the molecular pathway/s altered by thalidomide is unclear. Furthermore, studies looking at differential gene expression after direct thalidomide exposure have been carried out using microarray techniques in monkey embryos...
and in human and mouse embryonic stem cells. Expression levels of around 2000 genes were found to be altered following thalidomide exposure including those involved in cell differentiation, development, metabolism, cytoskeleton organization, limb and heart development and the immune response (Gao et al., 2014; Gao et al., 2015; Ema et al., 2010, Meganathan et al., 2012). Some of these changes may be primary, secondary or even tertiary. Indeed, the precise molecular pathway/s influenced by thalidomide remain to be fully determined. The possibility that there may be more than one direct molecular target and pathway affected by thalidomide is plausible.

A genomic study, carried out in human thalidomide affected patients, aimed to assess if a potential genetic susceptibility to thalidomide embryopathy exists by analysing the endothelial Nitric Oxide Synthase gene in thalidomide survivors and non-thalidomide affected individuals. It was observed that alleles relating to a reduced production of NO are found more frequently in thalidomide subjects. This not only reinforces the involvement of NO in thalidomide embryopathy but also the role for angiogenesis in thalidomide teratogenesis (Vianna et al., 2013).

5 Conclusion

Despite numerous studies and recent advances in our understanding, the mechanisms that result in thalidomide embryopathy are still not completely known. Actions upon blood vessels, induction of cell death and involvement of several gene targets including Cereblon and tubulin are all involved. Just how thalidomide exposure causes changes in molecular pathways and any interrelation among these pathways is unclear. Indeed multiple pathways may be affected to cause the different tissue specific damage. Currently blood vessels as a primary target tissue of thalidomide, which locally induces ROS and cell death in affected tissues, is a strongly favoured teratogenic mechanism of action of thalidomide (Vargesson, 2013; Vargesson, 2015; Figure 4).

Thalidomide was used to treat a range of conditions, including morning sickness, which typically occurs between week 4 and week 12 (although timing and severity can vary between women). Between weeks 4 and 9 major events in embryology
occur along with major cell signalling events, massive cell migration and tissue morphogenetic events. As we have outlined, angiogenesis and vascularisation is an essential step in tissue formation, outgrowth and maintenance. Smooth muscle negative vessels undergo rapid angiogenic changes and migration. Disruption of vessels or loss of vessels in forming tissues could result in cell death and localised ROS activity tissue loss with interrupted signalling devastating rapidly growing tissues and causing malformations. For example, phocomelia in the limbs could occur as vessels are prevented from vascularising the limb, which then starts to undergo cell death, loss of gene expression or gene misexpression. As the activity of the drug wears off, the remaining cells can be vascularised and undergo proliferation and the developing limb gene signalling pathways recover but as too few cells remain, only distal structures develop (Therapontos et al., 2009; Vargesson, 2009; Vargesson, 2015). Appearance of secondary cell types and their development into tissues, for example nerves, muscles and bones, will then be altered as the limb tissue is malformed or even missing (Vargesson, 2013; Vargesson, 2015).

By around week 9 the major tissues are formed and vasculature is also maturing through recruitment of smooth muscle, with reduced angiogenesis. Exposure to thalidomide does not appear to result in outwardly visible malformations after this stage. However, the fact that thalidomide acts in an antiangiogenic manner both in the early embryo and the adult suggests late embryonic exposure could damage physiological function of the internal organs as they mature and enlarge, since tissue expansion requires angiogenesis. The framework of thalidomide embryopathy as described above (Figure 4; and in further detail in Vargesson, 2015) is a good explanation for thalidomide-induced damage to the tissues. It can explain the range of damage and time sensitive nature of the induced damage. Malformations occur dependent upon the maturity of blood vessels and whether they are undergoing angiogenesis, and the chance of defects presenting is reduced as tissues and vessels mature (Therapontos et al., 2009; Vargesson and Laufer, 2001; Vargesson, 2013; Vargesson, 2015).

Challenges do remain, and these include to understand which molecular pathway, or multiple pathways, are affected by thalidomide to cause teratogenesis. We know several molecular targets of thalidomide, Cereblon and tubulin, and know many other gene profiles can be changed following thalidomide exposure. However, just how
thalidomide binding to these targets results in embryopathy is unclear. Understanding the molecular pathways and elucidating any other candidate targets may shed light on novel roles for genes and help to understand how birth defects can be prevented. In addition, determining if a form or analog of thalidomide can be produced with the clinical benefits (for example, an analog that will still treat leprosy) but without the side effect of birth defects, is a significant and essential challenge especially given the new generation of thalidomide affected children in Brazil (Beedie et al., In Press; Vargesson, 2015). Structural variants of thalidomide, for example, Lenalidomide and Pomalidomide, function slightly differently and are used clinically to treat inflammatory diseases and cancer, though with some species-specific teratogenic side-effects (Vargesson, 2013; Vargesson, 2015). Can a form of the drug be made or found that retains clinical relevance but without the drugs side-effects?

Great strides in our understanding of thalidomide-induced embryopathy have been made in the recent few years. Thalidomide’s use for treating inflammatory disorders in adult humans has increased interest in the drug and other uses for it. In addition, following the birth of recent thalidomide survivors in Brazil interest in determining the teratogenic mechanisms of the drug has also increased. Hopefully it will only be a matter of time before all the mechanisms this drug uses are finally determined and a safe form can be developed.

Acknowledgements

Apologies to the many papers we were unable to cite, due to space constraints. We thank Lynda Erskine, Shaunna Beedie and Chris Mahony for helpful discussions. Lucas Rosa Fraga is funded by a PhD scholarship from the Science without Borders program - CNPq Brazil - INAGEMP/ Grant CNPq 573993/2008-4. Alex J. Diamond is funded by a BBSRC DTP PhD Scholarship.
References


**Further Reading**


List of Abbreviations

1. BMP – bone morphogenetic protein
2. cGMP – cyclic guanosine monophosphate
3. COX2 – cyclooxygenase 2
4. CUL4A – cullin 4A
5. DDB1 – DNA damage-binding protein 1
6. ENL – erythema nodosum leprosum
7. FDA – US Food and Drug Administration
8. FGF – fibroblast growth factor
9. HHT – hereditary hemorrhagic telangiectasia
10. HUVEC – human umbilical vein endothelial cells
11. IL – interleukin
12. MM – multiple myeloma
13. NF-kB – nuclear factor - kappa beta
14. NO – nitric oxide
15. Roc1 – Regulator of cullin1
16. ROS – reactive oxygen species
17. sGC – soluble guanylyl cyclase
18. Shh – sonic hedgehog
19. TNFα – tumour necrosis factor alpha
20. VEGF – vascular endothelial growth factor
Table 1: A list of common defects seen in TE, the specific defects seen in each organ, and an explanation of each. Also listed are the time points at which thalidomide is taken that can result in each defect.

<table>
<thead>
<tr>
<th>Region Affected</th>
<th>Specific Defects Seen</th>
<th>Additional</th>
<th>Time Point of Exposure (Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limb</td>
<td>Reduced hand/footplate Digit effects</td>
<td></td>
<td>Thumb aplasia: 21-26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Triphalangeal thumb: 31-36</td>
</tr>
<tr>
<td></td>
<td>Amelia</td>
<td>Complete absence of limb</td>
<td>Upper limb: 24-29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower limb: 27-31</td>
</tr>
<tr>
<td></td>
<td>Phocomelia</td>
<td>Limb long bones are shortened or absent</td>
<td>Upper limb: 24-33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower limb: 28-33</td>
</tr>
<tr>
<td>Limb Girdles</td>
<td>Sharpened shoulder</td>
<td>Acromioclavicular joint is more prominent</td>
<td>Hip dislocation: 23-34</td>
</tr>
<tr>
<td></td>
<td>Hip joint / Pubic bone</td>
<td>Hypoplasia</td>
<td>Femoral hip hypoplasia: 28-33</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hip dysplasia: 20-24</td>
</tr>
<tr>
<td>Eye</td>
<td>Cataracts</td>
<td>20-24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Microphthalmia</td>
<td>Congenital small eye</td>
<td>24-30</td>
</tr>
<tr>
<td></td>
<td>Anophthalmos</td>
<td>Absence of eyeball</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Poor vision</td>
<td>Aberrant lacrimation</td>
<td>20-26</td>
</tr>
<tr>
<td></td>
<td>Abnormalities in eye movement</td>
<td>Colobomas</td>
<td>Derformity of iris and retina</td>
</tr>
<tr>
<td>Ear</td>
<td>Anotia</td>
<td>Complete absence of outer ear, results in deafness</td>
<td>20-24</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Inner ear defects: 24-33</td>
</tr>
<tr>
<td></td>
<td>Microtia</td>
<td>Part of the outer ear remains</td>
<td>24-33</td>
</tr>
<tr>
<td>Internal organs</td>
<td>Heart</td>
<td>Ventricular and atrial septum defects</td>
<td>22-31</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pulmonary stenosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patent ductus arteriosus</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>Lung malformation</td>
<td>29-32</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>Horseshoe, hypoplastic, rotated and ectopic malformations</td>
<td>Ectopic kidney: 24-29</td>
<td></td>
</tr>
<tr>
<td>Intestines</td>
<td>Duodenum</td>
<td>Duodenal atresia: 20-33</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duodenal stenosis: 27-34</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anal atresia</td>
<td>Anal atresia: 27-29</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gall bladder atresia</td>
<td>Rectal stenosis: 35-36</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pyloric stenosis</td>
<td>26-33</td>
<td></td>
</tr>
<tr>
<td>Urinary tract</td>
<td>Bladder atresia</td>
<td>28-29</td>
<td></td>
</tr>
<tr>
<td>Genitals</td>
<td>In males: absence of testes or testicular abnormalities.</td>
<td>Testicular agenesis: 31-33</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypospadias</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In females: malformations of uterus and reproductive tract</td>
<td>35-39 and 49-50</td>
<td></td>
</tr>
<tr>
<td>Nerves and CNS</td>
<td>Facial palsies</td>
<td>Ear defects are associated with cranial nerve palsies</td>
<td>Facial palsy: 20-26</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cranial palsy: 21-23</td>
</tr>
</tbody>
</table>

Figure Legends

Figure 1: Structures of thalidomide and its analogs Thalidomide enantiomers R (+) and S(-) can interchange at physiological pH (asterisk indicates chiral centre).

Figure 2: Therapeutic mechanisms of thalidomide in adults. Illustrated are the pathways through which thalidomide is thought to act in the treatment of HHT and Multiple Myeloma. (Adapted from Stewart, 2014; Lebrin et al., 2010)

Figure 3: Thalidomide time-sensitive window. Chart indicates the period (days and weeks post-fertilisation) in which the most common defects occur. See also Table 1. (Adapted from Vargesson, 2015; Miller et al., 2005).

Figure 4: Thalidomide and embryonic teratogenesis. Thalidomide has been shown to induce loss of blood vessels, increased cell death and reactive oxygen species resulting in embryonic damage. Thalidomide may cause teratogenesis through interaction with targets such as Cereblon, tubulin and/or sGC, interrupting blood vessel development and resulting in localised reactive oxygen species and cell death induction.
Figure 1
266x382mm (96 x 96 DPI)
Therapeutic Mechanisms of Thalidomide in the Adult

- Enhanced blood vessel stabilization
- Antiangiogenic at high doses
- Murinal cell activation
- Thalidomide
  - CRBN
  - DDB1
  - COL1A1
  - Ubiquitination
  - Ikaros
  - Aiolos
  - Degradation
- PDGF-B

Thalidomide in Myelodysplasia (MDS)

Multiple Myeloma
- Multiple Myeloma toxicity
- T and B cell function alteration

Thalidomide in Multiple Myeloma

444x366mm (300 x 300 DPI)
Figure 3
382x266mm (96 x 96 DPI)